The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: Therapeutic and cost outcomes over 2 years

Value in Health

Volumn 3, Issue 3, 2000, Pages 222-231

  McCombs, Jeffrey S ^a   Luo, Michelle ^a,b   Johnstone, Bryan M ^c,d   Shi, Lizheng ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Antipsychotic drug use patterns; Direct medical cost; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; DRUG COST; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA;

EID: 0033869728     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2000.33004.x     Document Type: Article

References (27)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154 (4 Suppl):1-63.
2. Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA (eds.). Psychiatric Disorders in America: The Epidemiological Catchment Area Study. New York, Toronto: The Free Press, 1991.
3. Rice DP, Miller LS. The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorius N (eds.). Handbook of Mental Health Economics and Health Policy (vol. 1). New York: John Wiley & Sons, 1996:321-34.
4. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.
5. Dickey B, Normand ST, Norton EC, Azeni H, Fisher W, Altaffer F. Managing the care of schizophrenia: lessons from a 4-year Massachusetts Medicaid study. Arch Gen Psychiatry 1996;53:945-52.
6. Fenton WS. Longitudinal course and outcome of schizophrenia. In: Moscarelli M, Rupp A, Sartorius N (eds.). Handbook of Mental Health Economics and Health Policy (vol. 1). New York: John Wiley & Sons, 1996:79-91.
7. Karasu T, Waltzman S, Lindermayer JP, Buckley P. The medical care of patients with psychiatric illness. Hosp Community Psychiatry 1980;31:463-71.
8. Jeste DV, Akiko J, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. Schizophr Bull 1996;22:413-30.
9. Bland RC, Parker JH, Orn H. Prognosis in schizophrenia: a ten-year follow-up of first admissions. Arch Gen Psychiatry 1976;33:949-54.
10. Tsuang MT, Woolson RF. Mortality in patients with schizophrenia, mania, depression and surgical conditions: a comparison with general population mortality. Br J Psychiatry 1977;130:162-6.
11. Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders: do suicides and accidental death solely account for this excess? Arch Gen Psychiatry 1978;35:1181-5.
12. Tsuang MT, Woolson RF, Fleming JA. Causes of death in schizophrenia and manic-depression. Br J Psychiatry 1980;136:239-42.
13. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 1980; 37:979-83.
14. Eaton WW, Day R, Kramer M. The use of epidemiology for risk factor research in schizophrenia: an overview and methodologic critique. In: Tsuang MT, Simpson JC (eds.). Handbook of Schizophrenia, vol 3: Nosology, Epidemiology and Genetics of Schizophrenia. New York: Elsevier, 1988:169-204.
15. Dingman CW, McGlashan TH. Discriminating characteristics of suicides: Chestnut Lodge follow-up sample including patients with affective disorder, schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 1986;74:91-7.
16. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 1978;35:153-5.
17. McGlashan TH. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14:515-42.
18. McCombs JS, Nichol NB, Johnstone BM, et al. Use patterns for conventional antipsychotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60(Suppl 19):5-11.
19. McCombs JS, Nichol NB, Johnstone BM, et al. Antipsychotic drug use patterns and the cost of treating schizophrenia. Psychiatr Services 2000; 51(4):525-527.
20. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994;32(3):214-26.
21. McCombs JS, Nichol MB, Stimmel GL. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Value Health 1999;2(4):269-80.
22. Johnstone BM, Croghan TW, Kessler RC, et al. Health insurance status and service utilization in a community sample of persons with non-affective psychosis: the National Cormorbidity Survey. Paper presented at the 125th Annual Meeting of the American Public Health Association; November, 1997; Indianapolis, IN.
23. Medical Care Statistics Section of the Fiscal Forecasting and Data Management Branch, Department of Health Services, State of California. MediCal Short Paid Claims Documentation; August, 1997; Sacramento, CA.
24. California's Medical Assistance Program. Annual Statistical Report: Calendar Year 1994. Medical Care Statistics Section, Department of Health Services, State of California; 1995; Sacramento, CA.
25. Health Care Financing Administration. Medicare and Medicaid statistical supplement. Health Care Financing Review 1996;17(Suppl):278 (Table 38).
26. Kane JM. Treatment of schizophrenia. Schizophr Bull 1987;13:133-56.
27. SAS, Version 6. Cary, NC: SAS Institute, 1993.